U.S. FDA Approves AbbVie's Parkinson's Drug Tavapadon
The U.S. FDA has approved tavapadon, a once-a-day pill for Parkinson's disease developed by AbbVie. AbbVie acquired the drug through its $8.7 billion purchase of Cerevel Therapeutics in 2023. This approval marks a significant step in Parkinson's treatment options, offering patients a new oral medication.
Hindu Health·10h ago



